Search

Your search keyword '"Shan, Tanyou"' showing total 19 results
Start Over Author "Shan, Tanyou"
19 results on '"Shan, Tanyou"'

1. Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.

Author

Jia, Ruinuo, Shan, Tanyou, Zheng, Anping, Zhang, Yaowen, Lu, Ping, Zhang, Guifang, Wang, Feng, Xu, Zhiqiao, Zheng, Guobao, Tang, Dongxia, Zhang, Weiguo, Li, Wanying, Li, Ruonan, Guo, Yibo, Liu, Lina, Luo, Xiaoyong, Zheng, Yingjuan, Chang, Zhiwei, Wang, Qiming, and Wang, Xinshuai

Published
2024
Full Text
View/download PDF

5. X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local-advanced squamous esophageal cancer (ESCC): 2021 update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Author

Jia, Ruinuo, primary, Shan, Tanyou, additional, Wan, Lixin, additional, Zheng, Anping, additional, Hui, Shuang, additional, Xu, Zhiqiao, additional, Wang, Feng, additional, Zheng, Guobao, additional, Lu, Ping, additional, Zhang, Guifang, additional, Zheng, Yingjuan, additional, Cui, Yanhui, additional, Luo, Xiaoyong, additional, Zhang, Weiguo, additional, Li, Wanying, additional, Li, Ruonan, additional, Zhou, Fuyou, additional, and Gao, Shegan, additional

Published
2022
Full Text
View/download PDF

8. X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Author

Jia, Ruinuo, primary, Shan, Tanyou, additional, Wan, Lixin, additional, Zheng, Anping, additional, Hui, Shuang, additional, Xu, Zhiqiao, additional, Wang, Feng, additional, Zheng, Guobao, additional, Lu, Ping, additional, Zhang, Guifang, additional, Zheng, Yingjuan, additional, Cui, Yanhui, additional, Luo, Xiaoyong, additional, Zhang, Weiguo, additional, Li, Wanying, additional, Li, Ruonan, additional, Zhou, Fuyou, additional, and Gao, Shegan, additional

Published
2020
Full Text
View/download PDF

10. Evaluation of Combined Argon Plasma Coagulation and Savary Bougienage for the Relief of Anastomotic-Stenosis after Esophageal Squamous Cancer Surgery

Author

Shegan Gao, Gang Liu, Xiaozhi Yuan, Xiang Yuan, Caihong Dong, Ruinuo Jia, Rui-Feng Guo, Shan Tanyou, Xiaoshan Feng, Edmund Wing To Tai, and Yi Zhang

Subjects
Adult, Male, medicine.medical_specialty, Esophageal Neoplasms, Argon plasma coagulation, macromolecular substances, Anastomosis, Disease-Free Survival, Stomach surgery, Esophagus, Carcinoma, medicine, Humans, Bougienage, Prospective Studies, Prospective cohort study, Aged, Aged, 80 and over, Argon Plasma Coagulation, business.industry, Anastomosis, Surgical, Stomach, Gastroenterology, Middle Aged, Esophageal cancer, medicine.disease, Combined Modality Therapy, Dilatation, Surgery, Esophagectomy, Stenosis, Carcinoma, Squamous Cell, Esophageal Stenosis, Female, Deglutition Disorders, business
Abstract

Background: Several endoscopic dilation techniques have been reported for treatment of anastomotic-stenosis of esophageal cancer, but the high incidence of dysphagia has remained unchanged. The aim of this study was to compare the effect of Argon Plasma Coagulation (APC) combined with Savary Bougienage (SB) compared to APC alone or SB alone for anastomotic-stenosis after radical operation for squamous cell carcinoma of the esophagus. Methods: Patients with anastomotic-stenosis that was diagnosed for the first time following esophageal squamous cell carcinoma resection surgery were randomly assigned to undergo APC combined with SB, APC alone, or SB alone. Primary endpoints were the dysphagia-free survival (DFS defined as the time from first dilatation of effectively relieved dysphagia to dysphagia relapse expressed in days) after 6 months of follow up. Results: A total of 90 patients from the Cancer Institute, First Affiliated Hospital of Henan University of Science and Technology were entered into the study (APC group, n = 30, SB group, n = 30, combination group [APC combined with SB], n = 30). Primary endpoints: 6 months after treatment, DFS of combination group (115.63 days; 95% CI, 105.31-125.95) was significantly longer than the APC alone group (39.53 days; 95% CI, 35.95-43.11, p = 0.000) and the SB alone group (16.93 days; 95% CI, 15.01-18.84, p = 0.000). No severe complications occurred within the three treatment groups. Conclusions: APC combined with SB was a safe and well-tolerated method for relieving dysphagia of esophageal squamous cell cancer patients with anastomotic-stenosis. (Registered with randomized controlled trials, ChiCRT, registration number ChiCTR-TRC-13003757.)

Published
2014
Full Text
View/download PDF

11. Concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with fluorouracil for treatment of squamous oesophageal cancer in Chinese patients (CRTCOESC): an interim report of a randomised, open-label, multicentre trial

Author

Jia, Ruinuo, primary, Shan, Tanyou, additional, Zhou, Fuyou, additional, Zheng, Anping, additional, Wan, Lixin, additional, Xu, Zhiqiao, additional, Zheng, Guobao, additional, Luo, Xiaoyong, additional, Zheng, Yingjuan, additional, Cui, Yanhui, additional, Zhang, Guifang, additional, Zhou, Dan, additional, Sun, Jiachun, additional, Kong, Guoqiang, additional, Yuan, Xiaozhi, additional, Yang, Ruina, additional, Ren, Jing, additional, Wang, Wei, additional, Wang, Xinshuai, additional, and Gao, Shegan, additional

Published
2017
Full Text
View/download PDF

12. A randomized, open-label, multicenter trial of the concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with 5-FU for Chinese squamous esophageal cancer: An interim report from CRTCOESC.

Author

Jia, Ruinuo, primary, Shan, Tanyou, additional, Zhou, Fuyou, additional, Zheng, Anping, additional, Wan, Lixin, additional, Xu, Zhiqiao, additional, Zheng, Guobao, additional, Luo, Xiaoyong, additional, Zheng, Yingjuan, additional, Cui, Yanhui, additional, Zhang, Guifang, additional, Zhou, Dan, additional, Sun, Jiachun, additional, Kong, Guoqiang, additional, Yuan, Xiaozhi, additional, Yang, Ruina, additional, Ren, Jing, additional, Wang, Wei, additional, Wang, Xinshuai, additional, and Gao, Shegan, additional

Published
2017
Full Text
View/download PDF

13. Apoptotic effects of Photofrin-Diomed 630-PDT on SHEEC human esophageal squamous cancer cells

Author

Gao, Shegan, Zhang, Mengxi, Zhu, Xiaojuan, Qu, Zhifeng, Shan, Tanyou, Xie, Xuanhu, Wang, Ying, and Feng, Xiaoshan

Subjects
Original Article
Abstract

Photodynamic therapy (PDT) using photofrin-II is a clinically effective treatment for both non-neoplastic and neoplastic diseases. Herein, we performed an in vitro experiment to study the anti-tumor effect and mechanisms of photofrin-II mediated PDT for esophageal squamous cell carcinoma (ESCC) cell line, SHEEC. In this study, human ESCC cell line SHEEC and parental normal cell line SHEE were used. The anti-tumor effect of PDT was determined by evaluating cell viability using CCK-8 assay, apoptosis and generation of reactive oxygen species (ROS). PDT induced significant apoptosis in SHEEC and SHEE cells in a time- and photofrin-II dose-dependent manner. Furthermore, PDT treatment induced significant death of SHEEC, instead of SHEE cells. The apoptotic outcome was accompanied by concurrent generation of ROS. In summary, PDT shed light on therapy of ESCC, functioning as a useful tool for ESCC clinical treatment, providing a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

Published
2015

15. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer

Author

Gao, Shegan, primary, Li, Shuoguo, additional, Ma, Zhikun, additional, Liang, Shuo, additional, Shan, Tanyou, additional, Zhang, Mengxi, additional, Zhu, Xiaojuan, additional, Zhang, Pengfei, additional, Liu, Gang, additional, Zhou, Fuyou, additional, Yuan, Xiang, additional, Jia, Ruinuo, additional, Potempa, Jan, additional, Scott, David A., additional, Lamont, Richard J., additional, Wang, Huizhi, additional, and Feng, Xiaoshan, additional

Published
2016
Full Text
View/download PDF

18. Comparative transcriptome analysis of the global circular RNAs expression profiles between SHEE and SHEEC cell lines.

Author

Sun J, Yuan X, Li X, Wang D, Shan T, Wang W, Wan Q, Wang X, Yan J, and Gao S

Abstract

Esophageal squamous cell carcinoma (ESCC) is widely regarded as one of the most lethal types of cancer around the world. The fact that early detection of ESCC could dramatically improve the treatment outcome of the patients has sparked considerable interest in searching for reliable and accurate diagnostic biomarkers. Recently, circular RNAs (circRNA) have emerged as a new type of non-coding RNAs with significant RNase resistance, wide abundance and remarkable internal diversity. There is also increasing evidence suggesting that circRNAs could be implicated in the pathogenesis of cancer and other diseases. In this study, we performed a comparative analysis of the global circRNA expression profiles in normal and malignant esophageal epithelial cell lines by a combination of RNA sequencing and bioinformatics analysis. We identified 813 significantly up-regulated and 445 down-regulated circRNA candidates, of which 32 were subsequently validated by quantitative real-time reverse transcription polymerase chain reaction analysis. The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells. Based on the obtained data, we constructed a circRNA-miRNA interaction network, in which circRNA9927-NBEAL1 represented the biggest node. Our study could lay the groundwork for further investigation concerning the pathological roles of circRNAs in ESCC., Competing Interests: None.

Published
2017

19. Apoptotic effects of Photofrin-Diomed 630-PDT on SHEEC human esophageal squamous cancer cells.

Author

Gao S, Zhang M, Zhu X, Qu Z, Shan T, Xie X, Wang Y, and Feng X

Abstract

Photodynamic therapy (PDT) using photofrin-II is a clinically effective treatment for both non-neoplastic and neoplastic diseases. Herein, we performed an in vitro experiment to study the anti-tumor effect and mechanisms of photofrin-II mediated PDT for esophageal squamous cell carcinoma (ESCC) cell line, SHEEC. In this study, human ESCC cell line SHEEC and parental normal cell line SHEE were used. The anti-tumor effect of PDT was determined by evaluating cell viability using CCK-8 assay, apoptosis and generation of reactive oxygen species (ROS). PDT induced significant apoptosis in SHEEC and SHEE cells in a time- and photofrin-II dose-dependent manner. Furthermore, PDT treatment induced significant death of SHEEC, instead of SHEE cells. The apoptotic outcome was accompanied by concurrent generation of ROS. In summary, PDT shed light on therapy of ESCC, functioning as a useful tool for ESCC clinical treatment, providing a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results